Please assess the completion status of the following clinical trial:

Trial Title: S0008: Chemotherapy Plus Biological Therapy in Treating Patients With Melanoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically proven melanoma of cutaneous origin or from unknown primary at initial presentation of primary or first clinically detected nodal or satellite/in-transit recurrence~  * No distant metastases~ * No melanoma of ocular, mucosal, or other non-cutaneous origin~* One of the following criteria must apply for patients with newly diagnosed melanoma OR a previously diagnosed primary with current subsequent, clinical, regional nodal disease and/or satellite/in-transit disease:~  * Ulcerated primary melanoma with 1 or more involved lymph nodes (micro/occult or macro/clinically overt)~ * Non-ulcerated or unknown primary melanoma with one macro/clinically overt lymph node metastasis, including a single matted nodal mass~    * No non-ulcerated or unknown primary tumor and a single micrometastatic lymph node~ * Non-ulcerated melanoma with two or more lymph node metastases (micro/occult or macro/clinically overt) and/or matted nodes~ * Any satellite/in transit metastasis with or without lymph node involvement~* Patients with recurrent disease must have recurrent disease in the regional nodal basin of a prior complete lymphadenectomy~* Multiple regional nodal basin involvement allowed if they are appropriate anatomic drainage basins for primary site~* Patients must be disease free at time of enrollment based on the following surgical criteria:~  * Patients at initial presentation of melanoma must undergo adequate wide excision of primary lesion~ * Patients with previously diagnosed melanoma must have all disease resected with pathologically negative margins and no disease at primary site or second resection of primary~ * Full lymphadenectomy required of all patients including those with positive sentinel nodes or positive satellite/in-transit metastasis~* No more than 56 days since prior lymphadenectomy OR surgery to remove recurrent disease after prior complete lymphadenectomy~* Must be willing to participate in minimal residual disease studies if registered on the study on 3/1/2003 or later~PATIENT CHARACTERISTICS:~Age:~* 18 and over~Performance status:~* Zubrod 0-1~Life expectancy:~* Not specified~Hematopoietic:~* Absolute granulocyte count at least 1,500/mm\^3~* Platelet count at least 100,000/mm\^3~Hepatic:~* Bilirubin no greater than 1.5 times upper limit of normal (ULN)~* SGOT or SGPT no greater than 2 times ULN~* LDH and alkaline phosphatase no greater than 2 times ULN (above normal value requires a contrast-enhanced CT scan or MRI of liver)~* No known recent hepatitis positivity by PCR~Renal:~* Creatinine no greater than 1.5 mg/dL OR~* Creatinine clearance at least 75 mL/min~Cardiovascular:~* No congestive heart failure~* No coronary artery disease~* No serious cardiac arrhythmia~* No prior myocardial infarction~* Normal cardiac stress test required if any of the following are present:~  * Over age 50~ * Abnormal EKG~ * History of cardiac disease~Pulmonary:~* No symptomatic pulmonary disease~Other:~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* No autoimmune disorders or conditions of immunosuppression~* No other prior malignancy within the past 5 years except the following:~  * Adequately treated basal cell or squamous cell skin cancer~ * Carcinoma in situ of the cervix~ * Adequately treated stage I or II cancer in remission~* HIV negative~* No known AIDS or HIV-1 associated complex~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* No prior immunotherapy, including interferon, interleukin, levamisole, or other biologic response modifiers~* No other concurrent biologic therapy~Chemotherapy:~* No prior chemotherapy (including infusion or perfusion therapy)~* No other concurrent chemotherapy~Endocrine therapy:~* No concurrent systemic corticosteroids or topical steroid creams~* Concurrent steroid antihistamines allowed if no alternative~* No concurrent hormonal therapy~Radiotherapy:~* No prior radiotherapy~  * Prior postlumpectomy radiotherapy for breast cancer allowed~* No concurrent radiotherapy~Surgery:~* See Disease Characteristics~* No concurrent surgery~Other:~* No concurrent anti-hypertensive medications (arm II only)~* No concurrent immunosuppressive agents~* No other concurrent anticancer therapy~* Antihistamines allowed if no alternative medication suitable

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm I (Type: ACTIVE_COMPARATOR): Patients receive interferon alfa IV on days 1-5 of weeks 1-4 followed by interferon alfa subcutaneously (SC) on days 1, 3, and 5 of weeks 5-52 in the absence of disease progression or unacceptable toxicity.
- Arm II (Type: EXPERIMENTAL): Patients receive cisplatin IV over 30 minutes followed by vinblastine IV on days 1-4. Patients also receive dacarbazine IV over 1 hour on day 1, interleukin-2 IV over 96 hours on days 1-4, and interferon alfa SC on days 1-5, 8, 10, and 12. In addition, patients receive filgrastim (G-CSF) SC on days 6-15. Treatment repeats every 3 weeks for 3 courses in the absence of disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete